Abstract | BACKGROUND: METHODS: Human gastrointestinal cancer xenografted tumors (one esophageal, one gastric, two colorectal, two biliary tract, and two pancreatic cancers) were transplanted into nude mice. The mice were given CR1505 at 250 mg/kg daily for 14 days, either subcutaneously or intragastrically, and the tumor volumes before and after treatment were compared. In vitro effects of CR1505 were assessed by measuring the DNA synthesis (3H-thymidine incorporation). RESULTS: CONCLUSIONS: These results suggest that CR1505 may specifically inhibit the growth of human pancreatic cancers and may be suitable for clinical study. However, its antiproliferative effect may not necessarily be dependent on its cholecystokinin-antagonism but may be mediated through the proteolytic enzymes found in the lysosomes of the pancreatic cancer cells.
|
Authors | Y Nio, M Tsubono, H Morimoto, K Kawabata, Y Masai, H Hayashi, T Manabe, M Imamura, M Fukumoto |
Journal | Cancer
(Cancer)
Vol. 72
Issue 12
Pg. 3599-606
(Dec 15 1993)
ISSN: 0008-543X [Print] United States |
PMID | 8252474
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Esters
- Guanidines
- camostat
- Gabexate
- loxiglumide
- Chloroquine
- DNA
- Cholecystokinin
- Proglumide
- Sincalide
|
Topics |
- Animals
- Cell Division
(drug effects)
- Chloroquine
(pharmacology)
- Cholecystokinin
(antagonists & inhibitors)
- DNA
(biosynthesis)
- Esters
- Gabexate
(analogs & derivatives)
- Guanidines
(pharmacology)
- Humans
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Neoplasm Transplantation
- Organ Culture Techniques
- Pancreatic Neoplasms
(drug therapy)
- Proglumide
(analogs & derivatives, pharmacology, therapeutic use)
- Sincalide
(pharmacology)
- Transplantation, Heterologous
|